US90400D1081
US90400D1081
Ultragenyx Pharmaceutical Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 673.000.000 | 560.000.000 | 20.2% |
| Cost of Revenue | 109.000.000 | 77.000.000 | 41.6% |
| Gross Profit | 564.000.000 | 483.000.000 | 16.8% |
| 1.099.000.000 | 1.019.000.000 | 7.9% | |
| Operating Income | -535.000.000 | -536.000.000 | 0.2% |
| Pretax Income | -571.000.000 | -567.000.000 | 0.7% |
| Net Income Common Stockholders | -575.000.000 | -569.000.000 | 1.1% |
| -- | -- | -- | |
| -- | -- | -- |